



UltraPulse

Above and Beyond



The Most Powerful CO₂ Laser in Aesthetic Medicine

UltraPulse® is designed to resurface the skin and reverse the effects of the environment, time, and natural aging. Its unrivaled deep reach is engineered to offer hope and provide life-changing results in the treatment of thick scars and lesions. The result... restored youth and remarkable outcomes with a precise, proven technology that goes Above and Beyond to exceed expectations.

DeepFX™ | ActiveFX™ Fractional Modes

- ✓ Great versatility and precision for all your resurfacing needs
- ✓ CoolScan™ technology for enhanced patient comfort

Exceptional Ablation/Coagulation Ratio

- ✓ Optimal clinical outcomes with minimal excess heating
- ✓ Proven efficacy in dozens of clinical studies and peer reviewed publications

Deepest Impact with SCAAR FX™ Mode

- ✓ Up to 4mm in a single pulse
- ✓ Ideal mode for treating deep, thick lesions

Shortest Pulse Duration

- ✓ Faster than the tissue relaxation time
- ✓ Minimizing thermal damage


UltraPulse Configuration	Treatment Mode	Description	Spot Size and Distribution
 DeepFX™ and TotalFX™	DeepFX™	Deep impact for treating wrinkles, acne scars and other deep cosmetic lesions	 ● 0.12 mm
	SCAAR FX™	Deepest impact in a single pulse for treating thick, complex lesions	
 ActiveFX™ and TotalFX™	PigmentFX™	Low, sub-ablative fluence for mild treatment of dyschromia	 1.3 mm
	ActiveFX™ / MaxFX™	Wide range of settings, including the CO ₂ Lite™, ActiveFX Gentle™, ActiveFX™ and MaxFX™ modes, for full and fractional treatment of texture and pigment inconsistencies	
 Any	PreciseFX™	Collimated 2.0mm handpiece for fast and precise tissue ablation and coagulation with consistent fluence	 2.0 mm
 Any	IncisionFX™	0.2mm & 1.0mm focused for clean, precise incisions	

Deep skin resurfacing

Before



After




Courtesy of Suzanne L. Kilmer, MD

Scar revision

Before



After



Courtesy of Jill S. Waibel, MD

Specifications

Platform	UltraPulse DeepFX™, ActiveFX™, TotalFX™
Technical Specifications	
Wavelength	10,600 nm
Laser Type	UltraPulse and CW
Power to Tissue	60 W
Peak Power	240 W
Spot Size	min. 0.12 mm / max. 2.0 mm TrueSpot™
Scan Size	Up to 15 x 15 mm
Density per Scan	fractional: 1-82%, full ablative: >100%
Full Resurfacing Capabilities	yes
Fractional Capabilities	yes
Incisional Capabilities	yes
Excisional Capabilities	yes
Aiming Beam	5 mW red diode laser, 635 nm, adjustable intensity
Beam Delivery	Articulated arm w/240 cm (94.5 in) reach, 360° rotation
Cooling	Self-contained, closed cycle
Warranty and Coverage	1 Year standard
Platform Specifications	
Electrical	100–240 VAC, 20 A max., 50/60 Hz
Weight	128 kg (280 lbs)
Dimensions (WxDxH)	34 cm x 51 cm x 144-195 cm (13.6 x 20 x 57-77 in)



RX only

Lumenis Ltd.
Yokneam Industrial Park
6 Hakidma Street P.O.B. 240
Yokneam 2069204, Israel
Tel: +972-4-959-9000

Lumenis (Germany) GmbH
Heinrich-Hertz-Str 3 D-63303
Dreieich-Dreieichenhain
GERMANY
Tel: +49 (0) 6103 8335 0

EMEA
Dreieich Dreieichenhain,
Germany
T +49 6103 8335 0
F +49 6103 8335 300

Roma, Italy
T +39 06 90 75 230
F +39 06 90 75 269

Hertfordshire, UK
T +44 20 8736 4110
F +44 20 8736 4119

JAPAN
Tokyo, Japan
T +81 3 6743 8300
F +81 3 6743 8301

AMERICAS
San Jose, CA, USA
T +1 408 764 3000
+1 877 586 3647
F +1 408 764 3999

ASIA PACIFIC
Beijing, China
T +86 10 5737 6677
F +86 10 5737 6767

Gurgaon, India
T +91 124 422 07 95

Kowloon, Hong Kong
T +852 217 428 00
F +852 272 251 51

Warnings and risks

CO₂ lasers are intended solely for use by physicians trained in the use of the Carbon Dioxide laser (10.6 μm) wavelength. Incorrect treatment settings or misuse of the technology can present risk of serious injury to patient and operating personnel. Risks that may be associated with any CO₂ laser procedure may include change of pigmentation, infection, erythema, skin induration or scarring. Read and understand the CO₂ systems and accessories operator manuals for a complete list of intended use, contraindications and risks. The use of Lumenis® CO₂ laser is contraindicated where a patient has taken Accutane (Isotretinoin) within the past 6-12 months, has a history of keloid formation and demonstrate excessive or unusually prolonged erythema

© LUMENIS LTD 2019

PB-2012536 Rev A